Jazz Pharmaceuticals plc JAZZ
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +27.05%
- 1 year
- +58.46%
- Open
- 209.63
- Prev close
- 207.83
- Mkt cap
- 14.02B
- Vol
- 1.22M
- Avg vol
- 889.51K
- EPS
- 14.59
- P/E
- 14.80
- Div yield
- 0.00%
More statistics
- Low
- 209.36
- High
- 216.38
- Forward P/E
- 8.64
- Beta
- 0.37
- Short ratio
- 6.86
- Inst. own
- 103.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 232.61
- 200-d avg
- 216.40
- 1y target
- 295.36
MAX chart
Events in this range
- Aug 5, 2025Earnings: -8.25; estimate -6.12; surprise -34.8%
- Nov 5, 2025Earnings: 8.13; estimate 5.95; surprise 36.64%
- May 5, 2026Earnings: 6.34; estimate 4.64; surprise 36.64%
- Aug 3, 2026Earnings: 5.71; estimate 6.18; surprise -7.61%
- Oct 7, 2026Rating: Truist Securities · Buy → Buy
- Nov 2, 2026Earnings: —; estimate -4.05; surprise —%
Signals (74)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| RSI: Overbought | Apr 1, 2026 | 7 months ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| SMA: Bearish | Apr 1, 2025 | 1 year ago |
| SMA: Bearish | Mar 1, 2025 | 1 year ago |
| SMA: Bullish | Feb 1, 2025 | 1 year ago |
| SMA: Bullish | Nov 1, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 1, 2024 | 1 year ago |
| SMA: Bearish | Sep 1, 2024 | 2 years ago |
| SMA: Bullish | Aug 1, 2024 | 2 years ago |
| SMA: Bearish | Sep 1, 2023 | 3 years ago |
| SMA: Bullish | Aug 1, 2023 | 3 years ago |
| SMA: Bearish | Feb 1, 2023 | 3 years ago |
| SMA: Bearish | Feb 1, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 1, 2023 | 3 years ago |
| SMA: Bullish | Nov 1, 2022 | 4 years ago |
| SMA: Bullish | Nov 1, 2022 | 4 years ago |
| MACD: Buy Signal | Nov 1, 2022 | 4 years ago |
| SMA: Bearish | Sep 1, 2022 | 4 years ago |
| SMA: Bearish | Sep 1, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 1, 2022 | 4 years ago |
| MACD: Buy Signal | Apr 1, 2022 | 4 years ago |
| SMA: Bullish | Mar 1, 2022 | 4 years ago |
| SMA: Bullish | Mar 1, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 1, 2021 | 5 years ago |
| SMA: Bearish | Aug 1, 2021 | 5 years ago |
| SMA: Bearish | Aug 1, 2021 | 5 years ago |
| SMA: Bullish | Sep 1, 2020 | 6 years ago |
| MACD: Buy Signal | Sep 1, 2020 | 6 years ago |
| SMA: Bullish | Aug 1, 2020 | 6 years ago |
| SMA: Bearish | Feb 1, 2020 | 6 years ago |
| MACD: Sell Signal | Feb 1, 2020 | 6 years ago |
| SMA: Bearish | Jan 1, 2020 | 6 years ago |
| MACD: Buy Signal | Dec 1, 2019 | 6 years ago |
| SMA: Bullish | Nov 1, 2019 | 7 years ago |
| SMA: Bullish | Nov 1, 2019 | 7 years ago |
| SMA: Bearish | Aug 1, 2019 | 7 years ago |
| SMA: Bullish | Jun 1, 2019 | 7 years ago |
| SMA: Bearish | Dec 1, 2018 | 7 years ago |
| MACD: Sell Signal | Dec 1, 2018 | 7 years ago |
| SMA: Bearish | Oct 1, 2018 | 8 years ago |
| SMA: Bullish | Mar 1, 2018 | 8 years ago |
| SMA: Bullish | Jan 1, 2018 | 8 years ago |
| SMA: Bearish | Oct 1, 2017 | 9 years ago |
| SMA: Bearish | Oct 1, 2017 | 9 years ago |
| SMA: Bullish | Jun 1, 2017 | 9 years ago |
| SMA: Bearish | May 1, 2017 | 9 years ago |
| SMA: Bullish | Apr 1, 2017 | 9 years ago |
| MACD: Buy Signal | Apr 1, 2017 | 9 years ago |
| SMA: Bullish | Feb 1, 2017 | 9 years ago |
| SMA: Bearish | Aug 1, 2016 | 10 years ago |
| SMA: Bullish | Apr 1, 2016 | 10 years ago |
| SMA: Bearish | Dec 1, 2015 | 10 years ago |
| SMA: Bullish | Nov 1, 2015 | 11 years ago |
| SMA: Bearish | Sep 1, 2015 | 11 years ago |
| SMA: Bearish | Aug 1, 2015 | 11 years ago |
| MACD: Sell Signal | Mar 1, 2015 | 11 years ago |
| MACD: Buy Signal | May 1, 2013 | 13 years ago |
| RSI: Overbought | May 1, 2013 | 13 years ago |
| MACD: Sell Signal | Nov 1, 2012 | 14 years ago |
| SMA: Bullish | Sep 1, 2012 | 14 years ago |
| MACD: Buy Signal | Sep 1, 2012 | 14 years ago |
| RSI: Overbought | Sep 1, 2012 | 14 years ago |
| SMA: Bearish | Aug 1, 2012 | 14 years ago |
| MACD: Sell Signal | Jul 1, 2012 | 14 years ago |
| SMA: Bullish | Jun 1, 2012 | 14 years ago |
| SMA: Bearish | May 1, 2012 | 14 years ago |
| RSI: Overbought | Nov 1, 2010 | 16 years ago |
| SMA: Bullish | Sep 1, 2010 | 16 years ago |
| SMA: Bearish | Aug 1, 2010 | 16 years ago |
| SMA: Bullish | Jul 1, 2010 | 16 years ago |
| SMA: Bearish | May 1, 2010 | 16 years ago |
| SMA: Bullish | Jun 1, 2009 | 17 years ago |
Key statistics
- Market cap
- 14.02B
- Enterprise value
- 15.70B
- Trailing P/E
- 14.80
- Forward P/E
- 8.64
- PEG ratio
- 0.96
- Price / sales
- 3.05
- Price / book
- 2.91
- EPS (TTM)
- 14.59
- Beta
- 0.37
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 20.45%
- Revenue (TTM)
- 4.60B
- Revenue growth
- 15.50%
- Free cash flow
- 1.43B
- Total cash
- 2.20B
- Total debt
- 4.41B
- Return on equity
- 22.11%
- Shares outstanding
- 64.91M
- Short % of float
- 9.30%
- 50-day average
- 232.61
- 200-day average
- 216.40
Analyst view
Consensus: strong buy
- Target (low)
- 225.00
- Target (mean)
- 295.36
- Target (high)
- 337.00
- Strong buy7
- Buy13
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate -2.21.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | -4.05 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | 6.18 | 5.71 | -0.47 | -7.61% |
| May 5, 2026 | Mar 31, 2026 | 4.64 | 6.34 | +1.70 | +36.64% |
| Feb 24, 2026 | Dec 31, 2025 | 6.52 | 6.64 | +0.12 | +1.84% |
| Nov 5, 2025 | Sep 30, 2025 | 5.95 | 8.13 | +2.18 | +36.64% |
| Aug 5, 2025 | Jun 30, 2025 | -6.12 | -8.25 | -2.13 | -34.80% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 21, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 8, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 7, 2026 | Truist Securities | main | Buy | Buy |
| Sep 30, 2026 | Citigroup | init | — | Buy |
| Sep 11, 2026 | UBS | main | Buy | Buy |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Ireland
- Website
- jazzpharma.com
News
- JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300
- Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine
- Jazz Pharmaceuticals Estimates $755M Pre-Tax Acquired IPR&D Charge From Actio Biosciences Acquisition; Expected $11.00 Negative Impact On Both GAAP And Adjusted EPS In Q3 2026
- Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for
- Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
- Jazz Pharmaceuticals Presents Data From Its Phase 3 HERIZON-GEA-01 Study Of Ziihera In Combination With Chemotherapy At ESMO Congress 2026 To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma
- Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
- Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314
- Jazz Pharmaceuticals PLC $JAZZ Position Lifted by CWA Asset Management Group LLC
- Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
Your note
Sign in to keep a note on JAZZ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COZADD BRUCE C | Director | Sale | Sep 30, 2026 | 345,875 |
| ENRIGHT PATRICK G. | Director | Stock Award(Grant) | Aug 4, 2026 | 22,984 |
| GALA RENEE D | Chief Executive Officer | Sale | Oct 5, 2026 | 141,394 |
| HENDERSON MARY ELIZABETH | Officer | Sale | Feb 25, 2026 | 28,728 |
| IANNONE ROBERT | Officer | Conversion of Exercise of derivative security | Aug 26, 2026 | 65,686 |
| JOHNSON PHILIP L | Chief Financial Officer | Stock Award(Grant) | Feb 25, 2026 | 62,223 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.19% | 5,968,603 | 1.29B | Jun 29, 2026 |
| FMR, LLC | 7.10% | 4,609,326 | 995.52M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.68% | 3,036,213 | 655.76M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.20% | 2,729,650 | 589.55M | Jun 29, 2026 |
| Capital World Investors | 4.16% | 2,697,610 | 582.63M | Jun 29, 2026 |
| LSV Asset Management | 3.50% | 2,275,145 | 491.39M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 2,312,286 | 499.41M | Sep 29, 2026 |
| AMERICAN FUNDS FUNDAMENTAL INVESTORS | 2.93% | 1,900,000 | 410.36M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.92% | 1,892,522 | 408.75M | Jun 29, 2026 |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | 2.41% | 1,561,563 | 337.27M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.11% | 1,366,767 | 295.19M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.33% | 865,937 | 187.03M | Jun 29, 2026 |